Modulation of carcinogenic response and antioxidant enzymes of rats administered with 1,2-dimethylhydrazine by Picroliv.
The effect of Picroliv treatment on the carcinogenic response and, hepatic and renal antioxidant enzymes of rats administered with 1,2-dimethylhydrazine hydrochloride (DMH) was studied in male Sprague-Dawley rats. DMH-induced hepatic carcinogenic response and necrosis were inhibited by oral administration of Picroliv (40 and 200 mg/kg). Liver gamma-glutamyl transpeptidase, which was elevated to 0.41 +/- 0.06 nmol/mg protein by DMH administration was found to be reduced to 0.22 +/- 0.04 and 0.18 +/- 0.03 nmol/mg protein by Picroliv treatment 40 and 200 mg/kg, respectively. Elevated number of Argyrophilic Nucleolar Organizer Region dots and clusters, an index of proliferation, of DMH treated rat liver was reduced by Picroliv treatment. DMH-induced depletion of hepatic and renal antioxidant enzymes such as catalase and superoxide dismutase levels were restored to normal by Picroliv treatment. Picroliv treatment reduced the DMH-induced elevation of lipidperoxidation in liver, kidney and serum. Elevated levels of serum total bilirubin by DMH administration was reduced by Picroliv treatment. Depleted renal glutathione S-transferase and hepatic glutathione levels after DMH administered rats were found to be significantly increased by Picroliv treatment. Histological analysis of the DMH administered rat liver showed hepatic cell necrosis, coalescent nodular areas and cystic hyperplasia of the bile ducts with inflammation. Picroliv treated liver resembled normal liver except the presence of a few degenerating cells. Renal anatomy was not altered by DMH administration.
Rajeshkumar
N V
NV
Amala Cancer Research Centre, Thrissur, Kerala 680 553, India.
Kuttan
Ramadasan
R
D000284:Administration, Oral; D000818:Animals; D001652:Bile Ducts / Q000473:pathology; D001663:Bilirubin / Q000097:blood; D002273:Carcinogens / Q000633:toxicity; D002374:Catalase / Q000378:metabolism*; D002455:Cell Division / Q000187:drug effects; D002934:Cinnamates / Q000627:therapeutic use*; D004127:Dimethylhydrazines / Q000633:toxicity; D005978:Glutathione / Q000378:metabolism; D006027:Glycosides / Q000627:therapeutic use*; D007668:Kidney / Q000187:drug effects / Q000201:enzymology; D015227:Lipid Peroxidation / Q000187:drug effects; D008099:Liver / Q000187:drug effects / Q000201:enzymology; D008114:Liver Neoplasms, Experimental / Q000201:enzymology* / Q000473:pathology / Q000517:prevention & control*; D008297:Male; D009336:Necrosis; D009697:Nucleolus Organizer Region / Q000378:metabolism; D010936:Plant Extracts / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013482:Superoxide Dismutase / Q000378:metabolism*; D014641:Vanillic Acid / Q000627:therapeutic use*; D005723:gamma-Glutamyltransferase / Q000378:metabolism
D002273:Carcinogens; D002934:Cinnamates; D004127:Dimethylhydrazines; D006027:Glycosides; D010936:Plant Extracts; C057463:kutkin; D002374:Catalase; D013482:Superoxide Dismutase; D005723:gamma-Glutamyltransferase; D005978:Glutathione; D014641:Vanillic Acid; D001663:Bilirubin